Table 2.

Global clinical benefits following re-irradiation (re-RT) of all patients (n = 31; Mann–Whitney U test p-value = 0.671) and the detailed clinical benefits of well-documented patients (n = 25) grouped according to the re-RT dose given (<20 Gy versus ≥20 Gy).

Re-RT dose given (Gy) Clinical benefits		< 20 (n = 14)		≥ 20 (n = 17)
Global clinical benefits (n = 31)
	Responding	10	71%	14	82%
	Non-responding	4	29%	3	18%
		< 20 (n = 13)		≥ 20 (n = 12)
Detailed clinical benefits (n = 25)
	Cranial nerve	7		4
	Long tract	6		4
	Cerebellar	3		8
	Fatigue	1		5
	Headaches	2		3

A difference appears to exist (23% versus 67%, chi-square p-value = 0.028) in improvement of cerebellar signs between the two groups (<20 Gy versus ≥20 Gy).